Lipoxygenase metabolism: roles in tumor progression and survival

被引:234
作者
Pidgeon, Graham P. [1 ]
Lysaght, Joanne
Krishnamoorthy, Sriram
Reynolds, John V.
O'Byrne, Ken
Nie, Daotai
Honn, Kenneth V.
机构
[1] St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Dept Clin Surg, Dublin 8, Ireland
[2] St James Hosp, Trinity Coll, Dept Clin Surg, Dublin, Ireland
[3] St James Hosp, Trinity Coll, Dept Haematol, Dublin, Ireland
[4] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48202 USA
[5] St James Hosp, Trinity Coll, Dept Clin Med, Dublin, Ireland
[6] So Illinois Univ, Sch Med, Inst Canc, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA
关键词
lipoxygenase; tumor survival; apoptosis; angiogenesis; immune suppression;
D O I
10.1007/s10555-007-9098-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The metabolism of arachidonic acid through lipoxygenase pathways leads to the generation of various biologically active eicosanoids. The expression of these enzymes vary throughout the progression of various cancers, and thereby they have been shown to regulate aspects of tumor development. Substantial evidence supports a functional role for lipoxygenase-catalyzed arachidonic and linoleic acid metabolism in cancer development. Pharmacologic and natural inhibitors of lipoxygenases have been shown to suppress carcinogenesis and tumor growth in a number of experimental models. Signaling of hydro[peroxy]fatty acids following arachidonic or linoleic acid metabolism potentially effect diverse biological phenomenon regulating processes such as cell growth, cell survival, angiogenesis, cell invasion, metastatic potential and immunomodulation. However, the effects of distinct LOX isoforms differ considerably with respect to their effects on both the individual mechanisms described and the tumor being examined. 5-LOX and platelet type 12-LOX are generally considered pro-carcinogenic, with the role of 15-LOX-1 remaining controversial, while 15-LOX-2 suppresses carcinogenesis. In this review, we focus on the molecular mechanisms regulated by LOX metabolism in some of the major cancers. We discuss the effects of LOXs on tumor cell proliferation, their roles in cell cycle control and cell death induction, effects on angiogenesis, migration and the immune response, as well as the signal transduction pathways involved in these processes. Understanding the molecular mechanisms underlying the anti-tumor effect of specific, or general, LOX inhibitors may lead to the design of biologically and pharmacologically targeted therapeutic strategies inhibiting LOX isoforms and/or their biologically active metabolites, that may ultimately prove useful in the treatment of cancer, either alone or in combination with conventional therapies.
引用
收藏
页码:503 / 524
页数:22
相关论文
共 159 条
  • [21] Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways.: Impact on inflammation and cancer
    Clària, J
    Romano, M
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) : 3431 - 3447
  • [22] INTEGRINS AND SIGNAL-TRANSDUCTION PATHWAYS - THE ROAD TAKEN
    CLARK, EA
    BRUGGE, JS
    [J]. SCIENCE, 1995, 268 (5208) : 233 - 239
  • [23] The arachidonate 12/15 lipoxygenases -: A review of tissue expression and biologic function
    Conrad, DJ
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 1999, 17 (1-2) : 71 - 89
  • [24] Cuendet M, 2000, Drug Metabol Drug Interact, V17, P109
  • [25] Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO
    D Basu, Gargi
    Tinder, Teresa L.
    Bradley, Judy M.
    Tu, Tony
    Hattrup, Christine L.
    Pockaj, Barbara A.
    Mukherjee, Pinku
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (04) : 2391 - 2402
  • [26] Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
    Datta, SR
    Dudek, H
    Tao, X
    Masters, S
    Fu, HA
    Gotoh, Y
    Greenberg, ME
    [J]. CELL, 1997, 91 (02) : 231 - 241
  • [27] 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation
    Ding, XZ
    Tong, WG
    Adrian, TE
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (05) : 630 - 636
  • [28] Prevention of αIIbβ3 activation by non-steroidal antiinflammatory drugs
    Domínguez-Jiménez, C
    Díaz-González, F
    González-Alvaro, I
    Cesar, JM
    Sánchez-Madrid, F
    [J]. FEBS LETTERS, 1999, 446 (2-3) : 318 - 322
  • [29] Prostaglandin E2 promotes integrin αVβ3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling
    Dormond, O
    Bezzi, M
    Mariotti, A
    Rüegg, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) : 45838 - 45846
  • [30] Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)
    Duffy, CP
    Elliott, CJ
    O'Connor, RA
    Heenan, MM
    Coyle, S
    Cleary, IM
    Kavanagh, K
    Verhaegen, S
    O'Loughlin, CM
    NicAmhlaoibh, R
    Clynes, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) : 1250 - 1259